Related Experiment Video
Updated: Jun 2, 2026
11:12
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
Novel cellular markers in breast cancer
1UNIV PARIS 07,ONCOL MOL LAB,F-75005 PARIS,FRANCE. FAC MED NIMES,LAB BIOL CELLULAIRE & IMMUNOGENET,NIMES,FRANCE. CNRS,INST JACQUES MONOD,LAB BIOCHIM DIFFERENTIAT,PARIS,FRANCE. UNIV PARIS 07,F-75005 PARIS,FRANCE. BREACH CANDY HOSP & RES CTR,BOMBAY 400026,MAHARASHTRA,INDIA.
International Journal of Oncology
|May 5, 2011
Summary
Parsi women show higher breast cancer rates. Researchers identified prosomal proteins (p23K, p30.33K) as potential markers for identifying high-risk populations and assessing breast cancer progression.
Area of Science:
- Oncology
- Cell Biology
- Immunology
Background:
- Epidemiological studies indicate Parsi women have a higher incidence and susceptibility to breast cancer.
- Identifying reliable biomarkers for early detection and risk stratification in breast cancer is crucial.
Purpose of the Study:
- To investigate the cellular distribution of prosomal proteins (p23K and p30.33K) as potential breast cancer biomarkers.
- To compare prosomal protein expression with the proliferation marker Ki-67 in different population groups.
Main Methods:
- Flow cytometry (FCM) and immunohistochemical methods were employed.
- Antibodies against prosomal proteins p23K and p30.33K were used.
- Expression levels were analyzed in Parsi and non-Parsi benign and malignant breast tissues, as well as European normal controls.
Main Results:
- Flow cytometry revealed higher labeling with p23K and p30.33K antibodies in Parsi benign and non-Parsi malignant samples compared to non-Parsi benign and European normal samples.
- Immunohistochemistry showed significantly higher p23K levels in Parsi and non-Parsi malignant tissues, and non-Parsi benign tissues.
- FCM analysis indicated significantly higher expression of both p23K and p30.33K in Parsi benign samples compared to non-Parsi samples.
Conclusions:
- The study suggests that prosomal antigens (p23K and p30.33K) may serve as valuable cell proliferation markers for breast cancer, comparable to Ki-67.
- Elevated prosomal protein expression in Parsi benign tumors suggests they may represent premalignant lesions, highlighting a potential risk factor in this population.
